Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies

Abstract

Data on the response to the COVID‐19 vaccine in patients with myeloid malignancy, who are at severe risk in case of infection, have not emerged. In a study of 69 patients with myeloid malignancies, including 46 patients with acute myeloid leukaemia (AML) and 23 patients with myelodysplastic syndrome (MDS), anti‐spike SARS‐CoV‐2 antibody titres were measured 3 months after the second mRNA‐based vaccination. Seroconversion rates for AML and MDS were 94.7% and 100% respectively, with no significant difference from healthy controls (HCs). Patients with MDS showed a significantly lower antibody titre than that in HCs or AML patients. In AML patients, the antibody titres were comparable to those in HCs when treatment was completed, but lower in patients under maintenance therapy. The response to COVID‐19 vaccine appears to be related to disease and treatment status. Patients with myeloid malignancies may be more responsive to vaccines than patients with lymphoid malignancies.

Is COVID vaccine effective in patients with myeloid malignancy?

“…A partial answer to the question of the outcome in patients with myeloid neoplasms is provided in this issue of the British Journal of Haematology. 13 Dr. Akio Mori and colleagues from Japan, report their experience with the humoral response to COVID vaccination in patients with myeloid disorders. They evaluated the humoral response to an mRNA‐based COVID‐19 vaccine in 69 patients, 46 with acute myeloid leukaemia (AML), and 23 with myelodysplastic syndromes (MDS).…”

“…A partial answer to the question of the outcome in patients with myeloid neoplasms is provided in this issue of the British Journal of Haematology 13 . Dr. Akio Mori and colleagues from Japan, report their experience with the humoral response to COVID vaccination in patients with myeloid disorders.…”

Humoral response to mRNA‐based COVID‐19 vaccine in patients with immune thrombocytopenia

“…All of the patients were vaccinated with two doses of an mRNA‐based COVID‐19 vaccine, either BNT162b2 or mRNA‐1273, and all of the patients visited the Blood Disorders Center at Aiiku Hospital during the period from 1 June 2021 to 31 March 2022. Anti‐SARS‐CoV‐2S immunoassays were performed at three months ± two weeks and six months ± four weeks after the second vaccination as previously reported 7,8 . All but one of the patients did not receive a third dose of the vaccine prior to the six‐month blood sampling, and this one patient was excluded from the six‐month analysis.…”

“…Anti-SARS-CoV-2S immunoassays were performed at three months ± two weeks and six months ± four weeks after the second vaccination as previously reported. 7,8 All but one of the patients did not receive a third dose of the vaccine prior to the six-month blood sampling, and this one patient was excluded from the six-month analysis. The diagnosis and response criteria of ITP were defined according to International Consensus Guidelines.…”

Adverse Hematological Effects of COVID-19 Vaccination and Pathomechanisms of Low Acquired Immunity in Patients with Hematological Malignancies

“…Of course, prevention of transmission within the context of vaccination has its own risks, as mentioned previously. In a study by Mori et al, [ 80 ] patients with myeloid malignancies, including both AML and MDS, were assessed 3 months after their second COVID-19 vaccine dose (BNT162b2 or mRNA-1273) and evaluated for anti-spike (S) SARS-CoV-2 antibodies. Among this patient population, seroconversion rates for AML and MDS were 94.7% and 100%, respectively.…”